Bell Investment Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$40.6K Sell
259
-4
-2% -$600 0.01% 315
2026
Q1
$40.2K Buy
263
+50
+23% +$7.66K 0.01% 289
2025
Q4
$29.4K Buy
213
+113
+113% +$14.8K ﹤0.01% 346
2025
Q3
$12.8K Sell
100
-89
-47% -$10.9K ﹤0.01% 551
2025
Q2
$22.9K Buy
189
+16
+9% +$1.8K ﹤0.01% 390
2025
Q1
$19.3K Sell
173
-19
-10% -$2.02K ﹤0.01% 400
2024
Q4
$18.7K Buy
192
+20
+12% +$2.13K ﹤0.01% 406
2024
Q3
$19.8K Hold
172
– – ﹤0.01% 406
2024
Q2
$18.3K Buy
172
+41
+31% +$4.12K ﹤0.01% 414
2024
Q1
$12.7K Hold
131
– – ﹤0.01% 505
2023
Q4
$13.2K Sell
131
-3
-2% -$290 ﹤0.01% 464
2023
Q3
$13.7K Buy
134
+23
+21% +$2.33K ﹤0.01% 399
2023
Q2
$11.2K Buy
111
+10
+10% +$1K ﹤0.01% 472
2023
Q1
$9.29K Buy
101
+63
+166% +$5.5K ﹤0.01% 511
2022
Q4
$3.45K Sell
38
-25
-40% -$2.11K ﹤0.01% 999
2022
Q3
$5K Buy
63
+7
+13% +$580 ﹤0.01% 698
2022
Q2
$5K Buy
+56
New +$4.91K ﹤0.01% 721
2021
Q4
$3K Sell
37
-4
-10% -$332 ﹤0.01% 1015
2021
Q3
$3K Buy
+41
New +$3.69K ﹤0.01% 952

Other funds holding NVS

Bell Investment Advisors's NVS Position: Q2 2026 in Review

Bell Investment Advisors reduced its Novartis (NVS) stake by 1.5% in Q2 2026, selling an estimated $600 and leaving 259 shares worth $40.6K. The position accounts for 0.01% of the portfolio, ranked #315.

Bell Investment Advisors first reported a position in NVS in Q3 2021 and has held it in 19 quarters since. 1,625 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Bell Investment Advisors held 259 shares of Novartis worth $40.6K as of Q2 2026.
  • Bell Investment Advisors sold 4 Novartis shares in Q2 2026, an estimated $600.
  • Novartis made up 0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #315 holding.
  • Bell Investment Advisors first reported a position in Novartis in Q3 2021 and has held it in 19 quarters since.
  • 1,625 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.